Phil Jeffrey

1.9k total citations
36 papers, 1.3k citations indexed

About

Phil Jeffrey is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Phil Jeffrey has authored 36 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Molecular Biology and 12 papers in Immunology. Recurrent topics in Phil Jeffrey's work include Monoclonal and Polyclonal Antibodies Research (10 papers), Drug Transport and Resistance Mechanisms (9 papers) and Toxin Mechanisms and Immunotoxins (7 papers). Phil Jeffrey is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), Drug Transport and Resistance Mechanisms (9 papers) and Toxin Mechanisms and Immunotoxins (7 papers). Phil Jeffrey collaborates with scholars based in United Kingdom, United States and Netherlands. Phil Jeffrey's co-authors include Scott Summerfield, S. E. Clarke, Rod A. Porter, Kevin D. Read, Tanja Obradovic, David J. Begley, Ismael J. Hidalgo, Sara Coggon, Leanne Cutler and Alexander J. Stevens and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Bioinformatics.

In The Last Decade

Phil Jeffrey

32 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Phil Jeffrey United Kingdom 16 549 524 294 207 156 36 1.3k
Bill J. Smith United States 20 467 0.9× 697 1.3× 185 0.6× 327 1.6× 348 2.2× 28 1.6k
Mikko Gynther Finland 23 733 1.3× 594 1.1× 319 1.1× 111 0.5× 41 0.3× 55 1.7k
Stefan Lundquist Sweden 15 458 0.8× 514 1.0× 191 0.6× 144 0.7× 71 0.5× 19 1.5k
Tadayuki Takashima Japan 24 257 0.5× 473 0.9× 82 0.3× 253 1.2× 173 1.1× 39 1.1k
Marialessandra Contino Italy 31 1.6k 2.9× 745 1.4× 495 1.7× 181 0.9× 62 0.4× 109 2.6k
Geri A. Sawada United States 21 489 0.9× 504 1.0× 98 0.3× 129 0.6× 75 0.5× 37 1.4k
Marie‐Anne Peyronneau France 18 260 0.5× 236 0.5× 159 0.5× 107 0.5× 158 1.0× 34 848
Tomoyuki Ohe Japan 23 429 0.8× 359 0.7× 160 0.5× 204 1.0× 225 1.4× 61 1.3k
Rudolf Gottschlich Germany 13 437 0.8× 232 0.4× 342 1.2× 115 0.6× 57 0.4× 19 1.0k
Swati S. More United States 21 450 0.8× 324 0.6× 66 0.2× 97 0.5× 67 0.4× 44 1.3k

Countries citing papers authored by Phil Jeffrey

Since Specialization
Citations

This map shows the geographic impact of Phil Jeffrey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phil Jeffrey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phil Jeffrey more than expected).

Fields of papers citing papers by Phil Jeffrey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phil Jeffrey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phil Jeffrey. The network helps show where Phil Jeffrey may publish in the future.

Co-authorship network of co-authors of Phil Jeffrey

This figure shows the co-authorship network connecting the top 25 collaborators of Phil Jeffrey. A scholar is included among the top collaborators of Phil Jeffrey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phil Jeffrey. Phil Jeffrey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Walsh, Stephen J., Johanna Lahdenranta, Philip Huxley, et al.. (2024). Abstract 5807: Bicycle Toxin Conjugates®for the treatment of solid tumors. Cancer Research. 84(6_Supplement). 5807–5807.
3.
Upadhyaya, Punit, Johanna Lahdenranta, Jun Ma, et al.. (2022). Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology. Journal of Medicinal Chemistry. 65(14). 9858–9872. 11 indexed citations
4.
Rigby, Michael, Gavin Bennett, Liuhong Chen, et al.. (2022). BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors. Molecular Cancer Therapeutics. 21(12). 1747–1756. 41 indexed citations
5.
Mudd, Gemma, Liuhong Chen, Katerine Van Rietschoten, et al.. (2022). Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer. Journal of Medicinal Chemistry. 65(21). 14337–14347. 58 indexed citations
6.
McKean, Meredith, Johanna C. Bendell, Daniel P. Petrylak, et al.. (2020). 599TiP BT8009-100 phase I/II study of the safety, pharmacokinetics, & preliminary clinical activity of BT8009 in patients with Nectin-4 expressing advanced malignancies. Annals of Oncology. 31. S500–S501. 5 indexed citations
7.
Rigby, Mike, Paul Beswick, Gemma Mudd, et al.. (2019). Abstract 4479: BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models. Cancer Research. 79(13_Supplement). 4479–4479. 6 indexed citations
8.
Henry, Katherine M., Julien Rougeot, Catherine A. Loynes, et al.. (2017). Expression and regulation of drug transporters in vertebrate neutrophils. Scientific Reports. 7(1). 4967–4967. 10 indexed citations
9.
Jeffrey, Phil & Scott Summerfield. (2009). Assessment of the blood–brain barrier in CNS drug discovery. Neurobiology of Disease. 37(1). 33–37. 75 indexed citations
10.
Summerfield, Scott & Phil Jeffrey. (2009). Discovery DMPK: changing paradigms in the eighties, nineties and noughties. Expert Opinion on Drug Discovery. 4(3). 207–218. 13 indexed citations
11.
Watson, Jeanette, Adam Lucas, Jean Viggers, et al.. (2009). Receptor Occupancy and Brain Free Fraction. Drug Metabolism and Disposition. 37(4). 753–760. 80 indexed citations
12.
Summerfield, Scott, Adam Lucas, Rod A. Porter, et al.. (2008). Toward an improved prediction of humanin vivobrain penetration. Xenobiotica. 38(12). 1518–1535. 77 indexed citations
13.
Jeffrey, Phil & Scott Summerfield. (2007). Challenges for blood–brain barrier (BBB) screening. Xenobiotica. 37(10-11). 1135–1151. 59 indexed citations
14.
Summerfield, Scott, Kevin D. Read, David J. Begley, et al.. (2007). Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction. Journal of Pharmacology and Experimental Therapeutics. 322(1). 205–213. 225 indexed citations
15.
Jeffrey, Phil, Eric Karran, Alan M. Palmer, & Geoffrey Stemp. (2006). Translational sciences-turning drug-like molecules into medicines.. PubMed. 19(10). 659–63. 2 indexed citations
16.
Summerfield, Scott & Phil Jeffrey. (2006). In vitro prediction of brain penetration – a case for free thinking?. Expert Opinion on Drug Discovery. 1(6). 595–607. 14 indexed citations
17.
Summerfield, Scott, Alexander J. Stevens, Leanne Cutler, et al.. (2006). Improving the in Vitro Prediction of in Vivo Central Nervous System Penetration: Integrating Permeability, P-glycoprotein Efflux, and Free Fractions in Blood and Brain. Journal of Pharmacology and Experimental Therapeutics. 316(3). 1282–1290. 138 indexed citations
18.
Farmer, Douglas G., Xiu‐Da Shen, Farin Amersi, et al.. (2004). CD62 Blockade with P-Selectin Glycoprotein Ligand-Immunoglobulin Fusion Protein Reduces Ischemia-Reperfusion Injury After Rat Intestinal Transplantation. Transplantation. 79(1). 44–51. 29 indexed citations
19.
Jeffrey, Phil. (2004). The Practice of Medicinal Chemistry. British Journal of Clinical Pharmacology. 57(5). 662–662. 78 indexed citations
20.
Clarke, S. E. & Phil Jeffrey. (2001). Utility of metabolic stability screening: comparison ofin vitroandin vivoclearance. Xenobiotica. 31(8-9). 591–598. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bill J. Smith Breakdown of academic impact, for papers by Mikko Gynther Breakdown of academic impact, for papers by Stefan Lundquist Breakdown of academic impact, for papers by Tadayuki Takashima Breakdown of academic impact, for papers by Marialessandra Contino Breakdown of academic impact, for papers by Geri A. Sawada Breakdown of academic impact, for papers by Marie‐Anne Peyronneau Breakdown of academic impact, for papers by Tomoyuki Ohe Breakdown of academic impact, for papers by Rudolf Gottschlich Breakdown of academic impact, for papers by Swati S. More
Rankless by CCL
2026